StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Investment analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

InspireMD Price Performance

NYSE:NSPR opened at $2.59 on Friday. The company has a 50 day moving average price of $2.83 and a 200-day moving average price of $2.75. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.80. The firm has a market cap of $76.90 million, a price-to-earnings ratio of -3.45 and a beta of 0.74.

Institutional Investors Weigh In On InspireMD

Institutional investors have recently modified their holdings of the business. Affiance Financial LLC grew its holdings in InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock valued at $497,000 after purchasing an additional 5,376 shares during the period. Renaissance Technologies LLC acquired a new stake in InspireMD in the 4th quarter valued at $27,000. Legato Capital Management LLC acquired a new stake in InspireMD in the 4th quarter valued at $47,000. Schonfeld Strategic Advisors LLC increased its holdings in InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after acquiring an additional 18,233 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after purchasing an additional 24,452 shares in the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.